SEC Form 4 · accession 0001562180-17-000573
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimi Iguchi
Officer — CFO & Treasurer
Period of report
Feb 6, 2017
Accepted (ET)
Feb 8, 2017 · 4:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $47.70 | Feb 6, 2017 | A | 45,000 | A | — | Feb 6, 2027 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1The securities awarded on 2/06/2017 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,625 shares of common stock shall vest on the one year anniversary of the Vesting Start Date with 16,875 shares vesting in 36 equal monthly installments thereafter. Options to purchase 22,500 shares of common stock shall vest periodically over the next four years upon the Company achieving certain milestones.